The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Go back to The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1| ALKERMES (NASDAQ: ALKS) | Delayed: 45.40 -0.09 (0.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.49 | 52 Week High | $80.71 | |||
| Open | $45.24 | 52 Week Low | $27.14 | |||
| Day High | $45.61 | P/E | 349.23 | |||
| Day Low | $44.72 | EPS | $0.13 | |||
| Volume | 516,142 | |||||
